Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda
By Sabela Ojea
Shares of Protagonist Therapeutics on Wednesday rose 5.6% to $26.41 in post-market trading after the company signed a worldwide license and collaboration agreement with Takeda for the development and commercialization of rusfertide.
The clinical-stage biopharmaceutical company said it will receive an upfront payment of $300 million, and that it's eligible to receive further payments depending on milestones.
Protagonist will remain responsible for research and development through the completion of the Phase 3 clinical trial for rusfertide and U.S. regulatory approval.
Takeda gets rights for its development, excluding the U.S., and is responsible for leading global commercialization activities.
Rusfertide is aimed at treating Polycythemia Vera, a rare blood disorder.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 31, 2024 18:58 ET (23:58 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?